Inhaled GM-CSF shows promise as a therapeutic to treat viral and bacterial pneumonia, but to date, no mouse model of inhaled GM-CSF has been described. We sought to: 1) develop a mouse model of the administration of aerosolized recombinant mouse GM-CSF; and 2) investigate the protection conferred by inhaled GM-CSF during influenza A virus (IAV) infection against secondary bacterial infection with pneumococcus. To assess lower respiratory tract delivery of aerosolized therapeutics mice were exposed to aerosolized fluorescein-labeled dextran non-invasively via an aerosolization tower, or invasively using a rodent ventilator. The efficiency of delivery to the lower respiratory tracts of mice was 0.01% non-invasively as compared to 0.3% invasively. The airway pharmacokinetics of inhaled GM-CSF fit a two compartment model with a terminal phase half-life of 1.3 h. To test if lower respiratory tract levels were sufficient for biological effect, mice were infected intranasally with IAV, treated with aerosolized recombinant mouse GM-CSF, then secondarily infected infected with . Inhaled GM-CSF conferred a significant survival benefit to mice against secondary challenge with (p<0.05). Inhaled GM-CSF did not reduce airway or lung parenchymal bacterial growth, but significantly reduced the incidence of bacteremia (p<0.01). However, GM-CSF overexpression during influenza virus infection did not affect lung epithelial permeability to FITC-dextran ingress into the bloodstream. Therefore, the mechanism of protection conferred by inhaled GM-CSF appears to be locally-mediated improved lung antibacterial resistance to systemic bacteremia during IAV infection.
Diosgenin, a steroidal saponin, and its analogues: Effective therapies against different chronic diseases.
August 13, 2020
Diets with lower carbohydrate concentrations improve insulin sensitivity in women with polycystic ovary syndrome: A meta-analysis.
March 23, 2020
Prolonged survival after disseminated Rhinocladiella infection treated with surgical excision and posaconazole.
February 14, 2020
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.